Assetmark Inc. Purchases 27,220 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Assetmark Inc. boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 230.6% during the third quarter, Holdings Channel.com reports. The fund owned 39,025 shares of the biotechnology company’s stock after acquiring an additional 27,220 shares during the period. Assetmark Inc.’s holdings in Sarepta Therapeutics were worth $4,874,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Innealta Capital LLC bought a new stake in shares of Sarepta Therapeutics in the second quarter worth about $31,000. New Covenant Trust Company N.A. purchased a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $32,000. Nkcfo LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at approximately $43,000. Riggs Asset Managment Co. Inc. lifted its stake in Sarepta Therapeutics by 33.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 75 shares during the period. Finally, UMB Bank n.a. lifted its stake in Sarepta Therapeutics by 105.9% in the third quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 197 shares during the period. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Transactions at Sarepta Therapeutics

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Andrew Chambers acquired 37,038 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

SRPT stock opened at $117.84 on Tuesday. The stock’s 50 day simple moving average is $125.56 and its 200 day simple moving average is $132.90. The company has a current ratio of 3.84, a quick ratio of 3.19 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 12-month low of $76.61 and a 12-month high of $173.25. The stock has a market capitalization of $11.26 billion, a PE ratio of 94.27 and a beta of 0.81.

Analyst Ratings Changes

Several brokerages have commented on SRPT. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Guggenheim lifted their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Evercore ISI decreased their target price on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Finally, Barclays dropped their price target on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. One analyst has rated the stock with a hold rating, twenty have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $181.33.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.